Q-omics provides the consensus-scored ZNF343 profile across patient tissues and cancer cell-line models. ZNF343 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ZNF343 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, ZNF343 RNA expression shows 20,934 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, HNSC, and UVM as cancer lineages where ZNF343 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF343 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF343 survival associations across molecular data types. ZNF343 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF343 RNA expression–survival associations across cancer types. High ZNF343 expression shows unfavorable associations in LIHC, MESO, COAD and KICH, but favorable associations in THYM and READ. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ZNF343 RNA expression.
This table summarizes ZNF343 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF343. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF343 shows lower tumor expression in THCA and higher tumor expression in HNSC, COAD, KIRC, STAD and LIHC. The HNSC box plot shows higher ZNF343 RNA expression in tumor versus normal tissue (log2 FC = +0.805, t-test p < 0.001).
This table shows molecular features associated with ZNF343 in patient tissues and cancer cell lines. In patient samples, ZNF343 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF343 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Lymphoma.
